[Corrections] Correction to Lancet Neurol 2026; 25: 136–46

Solomon T, Hooper C, Easton A, et al. Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial. Lancet Neurol 2026; 25: 136–46—In this Article, the dose of dexamethasone in the Summary, Methods and Research in Context panel should have read “10 mg four times daily for 4 days”. An NIHR disclaimer has been added. Additionally, the first sentence of the Results section should have read: “Between Sept 9, 2016, and Feb 21, 2022, 1427 patients with suspected encephalitis admitted to 53 hospitals in the UK.” Furthermore, in the sixth paragraph of the Results, in the fourth sentence, the number of patients in the control group tested for NMDAR antibodies in serum at 26 weeks has been corrected to four, and in the final sentence, “negative for NMDAR” has been corrected to “negative for NMDAR antibodies”.